About Jupiter Endovascular
Jupiter Endovascular is a Healthcare company based in Menlo Park (United States) founded in 2024. Minimally invasive medical devices for endovascular intervention are developed. Jupiter Endovascular has raised $61 million across 2 funding rounds from investors including Senvest Capital, LB Investment and Sonder Capital. Its chief executive, as recorded, is Carl St Bernard. Jupiter Endovascular offers products and services including Endoportal Control and Vertex Pulmonary Embolectomy System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Instylla, Spectrum Vascular and Access Point Technologies; 1 of its 3 listed competitors has raised funding.
Company details
Jupiter Endovascular was founded in 2024 and is based in Menlo Park, United States. Focus is placed on the development of minimally invasive medical devices within the endovascular intervention sector. The endoportal procedure is being advanced as a novel approach to endovascular interventions, incorporating Endoportal Control for improved precision and control in catheter-based methods. Operations center on innovation in device technology for vascular applications.
- Headquarters Menlo Park, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website jupiterendo.com
- Social LinkedIn
- Total Equity Funding$61M (USD)
in 2 rounds
- Latest Funding Round$40M (USD), Series B
Oct 2025
- InvestorsSenvest Capital
& 2 more
Products & Services of Jupiter Endovascular
Jupiter Endovascular offers a comprehensive portfolio of products and services, including Endoportal Control and Vertex Pulmonary Embolectomy System.
Technology merging surgical precision with catheter interventions for treatments.
System for treating pulmonary embolism through controlled endovascular procedures.
Funding Insights of Jupiter Endovascular
Jupiter Endovascular has successfully raised a total of $61M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61M
- Total Rounds 2
- Last Round Series B — $40M
- First Round $21M
(Aug 2024)
- Investors Count 3
All 2 funding rounds of Jupiter Endovascular with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $40M | Series B | – | Sonder Capital | |
| Aug 2024 | $21M | Series B | – | – |
3 investors in total: 3 institutional.
Investors in Jupiter Endovascular
Jupiter Endovascular has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Senvest Capital, LB Investment and Sonder Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage medtech startups are invested in by Sonder Capital. | sondercapital.com | San Carlos, United States | ||
Multiple sectors are invested in by this private equity firm. | 1999 | senvest.com | New York, United States | |
Growth-stage private equity investments are targeted across multiple sectors. | 1996 | lbinvestment.com | Seoul, South Korea |
Investor details for Jupiter Endovascular
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Jupiter Endovascular
5 people are tracked at Jupiter Endovascular (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Carl St Bernard | CEO | Leadership |
Chuck Love | Chief Science Officer | Leadership |
Carl J. St. Bernard | Chief Executive Officer | Leadership |
Fred Ong | CFO | Leadership |
Tara Howard | Clinical Research Specialist | Team |
Complete people profiles for Jupiter Endovascular
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Jupiter Endovascular
3 dated milestones of Jupiter Endovascular across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Jupiter Endovascular is founded.
- Funding First funding round of $21.0M.
- Funding Latest funding round, Series B, of $40.0M.
Competitors of Jupiter Endovascular
Jupiter Endovascular has 3 listed competitors in our database, 1 of them funded. They include Instylla, Spectrum Vascular and Access Point Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| instylla.com | 2017 | United States | $85.51M | 26 | Hydrogel technology is developed for embolization therapy applications. | |
| spectrumvascular.com | 2023 | White Plains, United States | Vascular access medical devices are developed by Spectrum Vascular. | |||
| accesspointus.com | 1999 | Rogers, United States | 1 | A range of EP diagnostic and ablation catheters is developed. |
Detailed competitors of Jupiter Endovascular
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Jupiter Endovascular
The website of Jupiter Endovascular (jupiterendo.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 25.2% vs previous month
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Jupiter Endovascular (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jupiter Endovascular
Complete news archive for Jupiter Endovascular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jupiter Endovascular
Jupiter Endovascular was founded in 2024.
Jupiter Endovascular is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Carl St Bernard is the CEO of Jupiter Endovascular, as recorded in our data.
Jupiter Endovascular is a funded company, having raised a total of $61M across 2 funding rounds to date. The company's 1st funding round was a Series B of $21M, raised on Aug 2024.
Jupiter Endovascular was founded in 2024 and is based in Menlo Park, United States. Focus is placed on the development of minimally invasive medical devices within the endovascular intervention sector. The endoportal procedure is being advanced as a novel approach to endovascular interventions, incorporating Endoportal Control for improved precision and control in catheter-based methods. Operations center on innovation in device technology for vascular applications.
Jupiter Endovascular's top competitors include Instylla, Spectrum Vascular and Access Point Technologies.
Jupiter Endovascular offers Endoportal Control and Vertex Pulmonary Embolectomy System.
Jupiter Endovascular has 3 investors. Key investors include Senvest Capital, LB Investment, and Sonder Capital.